Kuros Biosciences Ltd. Stock: price and insider trades · Switzerland

Every trade that managers of Kuros Biosciences Ltd. disclose to SIX SER is tracked on this page. The company sits in the Health Care sector. The last twelve months, up to 18 October 2026, brought 14 filings signed by 3 insiders.

The record shows 5 purchases on the open market worth €318k, made by 3 insiders, against 9 sales worth €9.7M by 2 insiders. The net balance comes to €9.4M on the selling side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Biggest ticket of the year: €2.9M, sold and made public on 20 October 2025. Among those who bought: 3 senior executives.

For context, the typical company on the same exchange (median of 178 companies) published 9 filings over the same period, against 14 filings here. Looking back to 2023, when coverage begins, insiders filed 23 purchases and 36 sales.

In the case of 1 purchase, another manager of the company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The clock since the last published purchase (22 September 2026) now reads 25 days. Half of the filings or more reach the SIX SER feed on the day of the trade. That lag is the time during which only the insider knows about the trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.

In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. This summary is built from SIX SER disclosures alone and does not predict where the share price will go.